FDA Staff Challenge Data On AstraZeneca PLC (AZN)'s Ovarian Cancer Drug Olaparib
6/24/2014 6:01:59 AM
(Reuters) - AstraZeneca Plc's experimental ovarian cancer drug, olaparib, showed an 83 percent reduction in the risk of disease progression, but a U.S. Food and Drug Administration staff review has questioned whether the result could be reproduced.
The company's shares fell 1.8 percent to 43.89 pounds on the London Stock Exchange.
Help employers find you! Check out all the jobs and post your resume.
comments powered by